Table of Contents
WASHINGTON — The Pharmaceutical Care Management Association (PCMA) has announced that Lucia Lebens has been named senior vice president of Federal Affairs and Political Strategy at PCMA, where she will lead the organization’s federal lobbying team.
“I am extremely pleased to welcome Lucia Lebens to the PCMA team. Her extensive experience leading federal advocacy teams will be a valuable addition to our talented group of federal lobbyists,” said PCMA President and CEO JC Scott. “The work of pharmacy benefit companies on behalf of 275 million Americans is vitally important to increasing access to high quality prescription drug coverage, securing savings on medications for patients, and enabling better health outcomes. Lucia bolsters our organization’s ability to promote the mission of pharmacy benefit companies and our continued effort to support policies that lower prescription drug costs for patients and allow health plan sponsors, like employers, the flexibility to manage their prescription drug benefits.”
Lebens was previously the vice president of Government Relations and Public Policy at Navient, where she led the company’s political, legislative, and regulatory bipartisan engagement strategy with federal and state elected officials, regulatory agencies, and key policymakers. Prior to Navient, Lebens served as the Director of Federal Government Affairs at ACA International and was Deputy Chief of Staff for a U.S. Senator. She was named a Top Lobbyist by The Hill in 2022.
“Pharmacy benefit companies are working every day to lower prescription drug costs for patients and the employers providing drug benefits, and I’m proud to stand behind pharmacy benefit companies in my position with PCMA,” said Lucia Lebens. “I look forward to working with Congress to solve the prescription drug affordability challenge that too many Americans face. PCMA will continue to fight for policies that increase competition and hold drug companies responsible for pricing and other tactics that are the primary obstacles to affordable drugs for all patients.”
